ArticleNature communications2025
The structural diversity of psychedelic drug actions revealed.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Structure-based design of subtype-selective psychedelic analogs.Nature communications · 2026Article
- Mechanistic Basis for 5-HTNature communications · 2026Article
- Inhalable Psychedelic 5-MeO-DMT Shows Promise in Treatment-Resistant Depression.Journal of medicinal chemistry · 2026Article
- Article
- Decoding Prolonged Residence Time of 5-HTJournal of chemical information and modeling · 2026Article
- Activity of Nonhallucinogenic Ibogalogs on Chemotherapy-Induced Peripheral Neuropathic Pain in Mice.ACS chemical neuroscience · 2026Article
- Correlation networks of blood proteins in the neuroimmunology of schizophrenia-replication and extension.Translational psychiatry · 2026Article
- Rewiring Receptor Activation: Mechanistic Insights into Toggle Switch Modulation by 25CN-NBx Compounds.ACS chemical neuroscience · 2026Article
- Psychedelics elicit their effects by 5-HTNature · 2026Article
- The 4-alkyl chain length of 2,5-dimethoxyamphetamines differentially affects in vitro serotonin receptor actions versus in vivo psychedelic-like effects.Molecular psychiatry · 2026Article
- Binding pose depth modulates photoswitchable ligands' efficacy at the 5-HTCommunications chemistry · 2026Article
- The science of psychedelic medicine.Nature medicine · 2026Review
- Regarding "The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses".Translational psychiatry · 2026Article
- Biased Signaling in Psychedelic Action.Annual review of pharmacology and toxicology · 2026Review
- Simple Analogs of the LSD D-Ring: A Consideration of Structure-Activity Relationships and Their Potential as Therapeutics.ACS chemical neuroscience · 2025Review
- The polypharmacology of psychedelics reveals multiple targets for potential therapeutics.Neuron · 2025Article
- Molecular dynamics study of differential effects of serotonin-2A-receptor (5-HT2AR) modulators.PLoS computational biology · 2025Article
- Biased signalingActa pharmaceutica Sinica. B · 2025Review
- Targeting the 5-HTJournal of medicinal chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
There is currently a resurgence in exploring the utility of classical psychedelics to treat depression, addiction, anxiety disorders, cluster headaches, and many other neuropsychiatric disorders. A biological target of these compounds, and a hypothesized target for their therapeutic actions, is the 5-HT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.